Search

Your search keyword '"Ladanyi A"' showing total 6,422 results

Search Constraints

Start Over You searched for: Author "Ladanyi A" Remove constraint Author: "Ladanyi A"
6,422 results on '"Ladanyi A"'

Search Results

51. Diabrotica v. virgifera Seems Not Affected by Entomotoxic Protease Inhibitors from Higher Fungi

52. Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations

54. Whole Cell MALDI Fingerprinting Is a Robust Tool for Differential Profiling of Two-Component Mammalian Cell Mixtures

55. Diagnostic yield and clinical relevance of expanded genetic testing for cancer patients

57. Improved prediction of immune checkpoint blockade efficacy across multiple cancer types

58. Use of massage therapy by mid-aged and older Australian women

59. Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers

60. Salt-Inducible Kinase 1 is a potential therapeutic target in Desmoplastic Small Round Cell Tumor

61. Pre‐operative pectoralis muscle area index is associated with biomarkers of inflammation and endotoxemia and predicts clinical outcomes after left ventricular assist device implantation: A cohort study.

64. TSC2-mutant uterine sarcomas with JAZF1-SUZ12 fusions demonstrate hybrid features of endometrial stromal sarcoma and PEComa and are responsive to mTOR inhibition

66. Somatic intronic TP53 c.375+5G mutations are a recurrent but under‐recognized mode of TP53 inactivation

67. Mutant-RB1 circulating tumor DNA in the blood of unilateral retinoblastoma patients: What happens during enucleation surgery: A pilot study.

68. Integrative Molecular Characterization of Malignant Pleural Mesothelioma

69. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context

70. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types

71. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types

72. lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer

73. Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas

74. A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples

75. Genomic and Functional Approaches to Understanding Cancer Aneuploidy

76. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images

77. Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation

78. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer

79. Systematic Analysis of Splice-Site-Creating Mutations in Cancer

80. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers

81. Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers

82. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas

83. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

84. Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines

85. Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas

86. Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

87. Author Correction: The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers

89. Diagnostic yield and clinical relevance of expanded genetic testing for cancer patients

90. Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers

92. Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets

94. Genomic and transcriptomic analysis of a diffuse pleural mesothelioma patient-derived xenograft library

95. The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers

96. Tracking the FDA precision oncology drug approval landscape in OncoKB.

97. Alterations in Sarcopenia Index are Associated with Inflammation, Gut and Oral Microbiota among Heart Failure, Left Ventricular Assist Device and Heart Transplant Patients.

98. Diffuse pleural mesotheliomas with genomic near-haploidization: a newly recognized subset with distinct clinical, histologic, and molecular features

99. Should Living Alone be an Absolute Contraindication to HeartMate 3 Implantation: A Single Center Experience

100. Sodium Glucose Co-Transporter 2 Inhibitor Use in HeartMate 3 Patients

Catalog

Books, media, physical & digital resources